BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.

A number of other equities research analysts have also weighed in on the stock. Ascendiant Capital Markets lowered their price objective on shares of BIOLASE from $3.50 to $2.00 and set a buy rating for the company in a report on Tuesday, September 3rd. Benchmark reiterated a speculative buy rating and set a $0.40 price target on shares of BIOLASE in a report on Monday, August 12th. Finally, Maxim Group lowered shares of BIOLASE from a strong-buy rating to a hold rating in a report on Friday, May 24th.

BIOLASE Stock Performance

Shares of NASDAQ:BIOL opened at $0.06 on Monday. The company has a 50 day moving average of $0.07 and a 200 day moving average of $0.12. The stock has a market cap of $1.90 million, a P/E ratio of 0.00 and a beta of 0.66. BIOLASE has a 12 month low of $0.04 and a 12 month high of $3.57.

BIOLASE (NASDAQ:BIOL) last issued its quarterly earnings data on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. BIOLASE had a negative net margin of 41.65% and a negative return on equity of 1,782.73%. The firm had revenue of $11.56 million for the quarter.

Institutional Trading of BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC boosted its position in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is currently owned by hedge funds and other institutional investors.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.